Navigation Links
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
Date:7/11/2014

SARASOTA, Fla., July 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"), has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND") application before granting the Company permission to start its clinical trial in the US.

Dr. Chris Chapman, RCP's President, commented, "We appreciate the agency's review and comments on our IND. When we receive the agency's official comments and/or recommendations, we will respond expeditiously. We look forward to moving this important product through the regulatory process."

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014.  We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

About Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for inflammatory conditions, clinical immunology, neurological disease and behavioral health.  Additionally, through its subsidiary RCP Development, the Company is engaged in the manufacturing and sale of nutraceutical dietary supplements designed to promote maintenance of a healthy metabolism and lifestyle. 

For more information, visit: http://www.rockcreekpharma.com

Logo - http://photos.prnewswire.com/prnh/20140711/126408

CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com

 


'/>"/>
SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. AMG Medical Inc. Selects Saddle Creek for Multichannel Fulfillment
2. A Forever Recovery Battle Creek, MI: Increasing Recreational Drug Use in Colleges Creates Risk for Addictions
3. Creekridge Capital Continues Vendor Growth within Technology
4. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
5. Creekridge Capital Announces Record Volume
6. Creekridge Capital Adds Revolving Credit Specialist
7. Creekridge Capital Expands Healthcare Sales Team
8. Creekridge Capital Launches Vendor Sales Training Program
9. Creekridge Capital Grows Healthcare Sales Team
10. Creekridge Breaks Monthly and Quarterly Volume Records
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
(Date:5/23/2016)... 23, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced ... Internship programs. The hands-on learning experience is a 12-week ... paid Fellowship and Internship programs ... Fellows and interns are provided optional housing free of ... at the Riverfront Residence Hall to foster communication ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health insurance ... 10% over last year, according to data in the forthcoming AIS’s Directory of ... stable, with a slight decrease in risk-based groups and a slight increase in ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, on May ... transplant in the United States . The 64-year-old patient who received the transplant had ... could restore not only a natural appearance, but also urinary and sexual function for ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... In light ... residents aware of the potential of contaminated well water throughout the Houston area. , ... supplied with well water that’s exposed to contaminants. Residents may not even be aware ...
(Date:5/24/2016)... ... 24, 2016 , ... Aloria Health Announces Opening of Eating ... , Aloria Health, specializing in a re-imagined, client-oriented approach to the treatment of ... treatment facility for outpatient, day treatment and residential care. Aloria Milwaukee will open ...
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion Safety Systems , ... labels , has been featured in the National Electrical Manufacturers Association’s (NEMA) newsletter, ... electroindustry professionals with manufacturer, regulatory, and standardization news. The publication is a bi-monthly ...
Breaking Medicine News(10 mins):